Between December 8 and December 10, 2025, SNY faced a series of analyst rating adjustments that tempered investor sentiment.

Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysemaAdditional orphan designation ...

Sanofi (EURONEXT: SAN) announced Wednesday that its investigational therapy, efdoralprin alfa, has received orphan drug ...

In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals ...

Investing.com -- Sanofi (EURONEXT:SAN) said Wednesday that its investigational therapy efdoralprin alfa has received orphan ...

December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: Fourth quarter & full year 2025 results (sanofi.com) As for each ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National ...

Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.

Pfizer Inc., AstraZeneca Plc and other companies have struck deals with the Trump administration in recent months ...

Earlier this year, Australia rolled out its newest screening program in 20 years, but can it reach those most at risk?

The "Malabsorption Syndrome Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Malabsorption Syndrome was valued at US$3.5 Billion in ...

Drugmaker InSilico Medicine has started taking orders from investors for its Hong Kong initial public offering. The company plans to issue 94.7 million shares at 24.05 Hong Kong dollars each, ...